- The US IPO market has raised significantly more capital in 2026 than during the same period last year, but delayed offerings and rising bond yields show that investors remain selective about valuations, profitability and the ability of newly listed companies to deliver on their growth plans.
The US initial public offering market is reopening, giving investors more opportunities to buy shares in companies making their public debuts. But the recovery is uneven, and a busy IPO calendar does not necessarily mean every new listing represents an attractive investment.
Through September 30, companies completed 83 traditional IPOs in the US, raising more than $120.2 billion, compared with 60 offerings that raised approximately $29.3 billion during the same period in 2025, according to PwC's third-quarter capital-markets review. Activity slowed toward the end of the third quarter as bond yields rose and several high-profile companies postponed their offerings.
The contrast is important for investors tracking upcoming IPOs in October 2026. More companies are testing public markets, but issuers still need to find buyers willing to accept their proposed valuations.
The market has also become more selective by industry. Biotechnology companies have been among the stronger performers, while some technology-related listings have encountered delays. The Wall Street Journal reported that 23 biotechnology companies completed IPOs during the first three quarters of 2026, nearly three times the eight recorded in all of 2025. About 65% of this year's biotech IPOs were trading above their offer prices at the end of September, according to William Blair data cited by the newspaper.
That performance does not guarantee similar returns for new listings. It does, however, show why investors should examine each company's finances, competitive position and offering price rather than treating the broader IPO recovery as a reason to buy indiscriminately.
Upcoming IPOs in October 2026: What Investors Should Watch
The active IPO pipeline includes companies from healthcare, technology and financial services. The IPO Boutique pipeline listed City Therapeutics, vVARDIS Holding and OPay among companies with recent filings or updates as of October 10.
Healthcare listings have been particularly active. TRex Bio and Retension Pharmaceuticals were among the biotechnology companies preparing to enter public markets in October, while the latest IPO filings database provides a way to track registration activity, proposed share offerings and pricing information as companies update their plans.
Investors should distinguish a company that has filed registration documents from one that has priced its IPO or begun trading. Expected dates can change, and a filing does not guarantee that an offering will proceed on schedule.
The recent withdrawal of Firmus' planned $5 billion offering is a reminder of that risk. The Australian AI infrastructure company, backed by Nvidia, abandoned its proposed IPO after struggling to attract sufficient investor demand at its intended valuation, according to Wealthier Today's report on the Firmus IPO withdrawal.
Oura, the smart-ring maker, also postponed its planned US listing. The delays suggest that companies may be willing to wait rather than accept valuations below their expectations.
For investors, the lesson is to monitor official company filings and exchange announcements instead of relying exclusively on IPO calendars or speculation about high-profile debuts. A company may have a compelling business, but the investment case can change materially depending on its final offer price, the number of shares sold and the amount of capital it receives.
The SpaceX IPO illustrates the difference between a company's public-market debut and its subsequent trading performance. Strong initial demand can push a stock above its offer price, but investors who buy after a sharp opening rally may face a different risk-and-return profile from those allocated shares at the IPO price.
How to Separate Strong IPOs From Market Hype
A promising IPO should offer more than a recognizable name or an exciting industry narrative. Investors need to assess whether the company's financial position and proposed valuation support the expectations embedded in the share price.
Revenue quality and profitability are a useful starting point. Investors should examine whether sales are recurring, whether growth depends on a small number of customers and whether the company is moving toward sustainable profits. Rapid revenue growth can be valuable, but it does not automatically translate into positive cash flow.
Valuation matters just as much. A company can have a strong business and still be a poor investment if its IPO price assumes years of exceptional growth. Investors should compare its valuation with publicly traded peers, taking into account differences in growth, margins, debt and business maturity.
The use of IPO proceeds also deserves scrutiny. Funds raised from newly issued shares can finance expansion, research, debt repayment or other corporate needs. When existing shareholders sell shares, however, some or all of the proceeds may go to those investors rather than the company. The prospectus should explain how the offering is structured.
Investors should also examine share dilution, voting rights, insider ownership and any lockup arrangements restricting early shareholders from selling. A large lockup expiration can increase the number of shares available for trading, potentially affecting the stock even if the underlying business has not changed.
Market conditions remain another consideration. Rising Treasury yields can make lower-risk bonds more competitive with growth stocks and increase the discount rate applied to future earnings. That can weigh on companies whose valuations depend heavily on profits expected many years from now.
The recent IPO slowdown reflects that tension. PwC's market review found that investors continued to prioritize valuation, durable growth, profitability and competitive differentiation. Those criteria matter more than the number of companies entering the market.
Finally, investors should read the company's SEC registration statement, including its risk factors, financial statements, related-party transactions and description of how the proceeds will be used. The final prospectus provides the most relevant basis for evaluating the actual offering rather than relying on promotional presentations or media attention.
The IPO market's recovery is creating more choices, but it is not removing the risks associated with newly listed stocks. Investors who focus on business fundamentals, valuation and the terms of each offering are better positioned to distinguish companies with credible long-term prospects from listings whose appeal rests mainly on hype.